Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

This article discusses literally a couple dozen vaccines and drugs that are in development for Ebola.  How is their testing being fast-tracked ?

 2013 Dec;27(6):565-83. doi: 10.1007/s40259-013-0046-1.
Choi JH1, Croyle MA.

Abstract

Ebola is a highly virulent pathogen causing severe hemorrhagic fever with a high case fatality rate in humans and non-human primates (NHPs). Although safe and effective vaccines or other medicinal agents to block Ebola infection are currently unavailable, a significant effort has been put forth to identify several promising candidates for the treatment and prevention of Ebola hemorrhagic fever. Among these, recombinant adenovirus-based vectors have been identified as potent vaccine candidates, with some affording both pre- and post-exposure protection from the virus. Recently, Investigational New Drug (IND) applications have been approved by the US Food and Drug Administration (FDA) and phase I clinical trials have been initiated for two small-molecule therapeutics: anti-sense phosphorodiamidate morpholino oligomers (PMOs: AVI-6002, AVI-6003) and lipid nanoparticle/small interfering RNA (LNP/siRNA: TKM-Ebola). These potential alternatives to vector-based vaccines require multiple doses to achieve therapeutic efficacy, which is not ideal with regard to patient compliance and outbreak scenarios. These concerns have fueled a quest for even better vaccination and treatment strategies. Here, we summarize recent advances in vaccines or post-exposure therapeutics for prevention of Ebola hemorrhagic fever. The utility of novel pharmaceutical approaches to refine and overcome barriers associated with the most promising therapeutic platforms are also discussed.

Similar Posts

FLCCC review/ meta-analysis of ivermectin now published–give a copy to your doctor

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 Kory, Pierre MD1,*; Meduri, Gianfranco Umberto MD2; Varon, Joseph MD3; Iglesias, Jose DO4; Marik, Paul E. MD5 American Journal of Therapeutics: May Jun 2021 – Volume 28 – Issue 3 – p e299-e318 Conclusions:  Meta-analyses based on 18 randomized…

Energy Department Now Using the “Misinformation” Meme against those who challenge safety of windmills on people living in their vicinity, with help from NPR

According to National Public Radio (your tax dollars at work),  “There’s another battle in the misinformation wars – renewable energy. False and misleading information about wind and solar is fueling opposition to projects across rural America.” “The spread of misinformation about solar and wind energy is leading some states and counties to restrict or even…

Why not a US investigation of the swine flu response?/ Alliance for Human Research Protection

The Alliance for Human Research Protection (AHRP) calls for an investigation ofconflicts of interest at Federal Agencies which spearheaded the excessive,expensive, and unjustifiable federal expenditure in response to the false SwineFlu “pandemic” in the U.S. Indeed, “off the record”, CDC even stage-managed media coverage of the epidemic. Issues requiring investigation: 1. BARDA (the Biomedical Advanced…

One Comment

Comments are closed.